Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Organisation › Details

Alcon Laboratories (UK) Ltd.

	Group	Novartis (Group)
	Industry	ophthalmic

	Region	United Kingdom (town unspecified)
	Country	United Kingdom (GB)
	City	n. a.
		Address record changed: 2011-05-15

Basic data	Employees	n. a.


		Record changed: 2023-07-10

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Novartis (Group)

[1] FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg....
[2] BioNTech SE. (3/20/24). "Press Release: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer". Mainz....
[3] Scinai Immunotherapeutics Ltd.. (2/13/24). "Press Release: Scinai Welcomes Liat Halpert as Head of Business Development and Sales". Jerusalem....
[4] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
[5] Calypso Biotech B.V.. (1/8/24). "Press Release: Calypso Enters into Agreement to Be Acquired by Novartis". Amsterdam....
[6] Shanghai Argo Biopharmaceutical Co., Ltd.. (1/7/24). "Press Release: Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis". Shanghai....
[7] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
[8] Legend Biotech Corporation. (11/13/23). "Press Release: Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3". Somerset, NJ....
[9] Sandoz Group AG. (10/4/23). "Press Release: Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines". Basel....
[10] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]